Astellas Pharma: Performance, Products, Pipeline and Potential
|
|
- Corey Elliott
- 6 years ago
- Views:
Transcription
1 Brochure More information from Astellas Pharma: Performance, Products, Pipeline and Potential Description: Astellas Pharma Inc was formed on 1st April 2005 from the merger of Yamanouchi and Fujisawa. The aim of Astellas is to secure a top share in the Japanese pharmaceutical market; the combined company now has 5,000 medical representatives, the largest among domestic pharmaceutical companies, and it aims to develop an even stronger sales and marketing infrastructure. The company also expects to be able to provide broad coverage for both primary care physicians and specialty markets in the US by leveraging the existing infrastructures to accelerate expansion of the US business. The merger of Yamanouchi and Fujisawa brought together two very complementary R&D pipelines, putting Astellas in a very strong position in the domestic Japanese market. The combined company has concentrated its core business on pharmaceuticals and related products, split into six key franchise fields and priority research areas; urology, inflammation, diabetes, infectious diseases, gastrointestinal disease and the central nervous system. Astellas has a number of licensed-in products, which have been proven overseas by partner companies. These products, such as Micardis, Luvox, Seroquel, Eligard and Myslee, are regarded as "Synergy Products'" by Astellas and should provide the foundation for future growth. Astellas is throwing its weight behind these products with support from all of its medical sales representatives and Area Marketing Supporters. For other key products Astellas has divided up its sales force into two: GA, which markets Yamanouchi products and CF, which markets the former Fujisawa products. The merger also enhanced the global reach of Astellas and it now has a strong base from which to begin to increase overseas sales without relying too heavily on partners to market its products. Most Japanese pharmaceutical companies are still struggling to achieve this aim, despite setting up overseas subsidiaries and sales offices. Astellas now has a significant global sales network that spans Japan, Europe and North America, and it can finally begin to make inroads in foreign markets through its own sales channels. Although recent years have seen declining sales in a number of its older products, Astellas' broad portfolio has enabled the accelerated transition of its late-stage products to regulatory submission in time to offset these declines. The greatest challenge for the company is expected to arise in fiscal 2009, when the US patent expiry in April 2008 of its blockbuster product Prograf is predicted to severely impact total company revenue. Losses incurred by the loss of exclusivity for this product are expected to be partially buffered by increasing sales of Vesicare and mainstay products such as Micardis. Contents: EXECUTIVE SUMMARY 5 Introduction 5 Current Financial Position 6 Company Performance 6 Business Segment Performance 6 Geographic Segment Performance 8 Company Strategy 14 R&D Strategy 14 Mergers, Acquisitions and Divestitures 15 Key Agreements 17 Production 18 Employees 18 Product Performance Forecasts 20 Pipeline Analysis 22 Key R&D Projects 22
2 Discontinued Projects 23 Conclusions 25 THERAPEUTIC ARE A FOCUS 29 R&D PIPELINE 30 CARDIOVASCULAR 32 Marketed Products 32 Adenocard 32 Adenoscan 33 Cibenol 34 Dorner 35 Frandol 37 Hypoca/Cyress 38 Lexiscan 39 Lipitor 40 Micardis 42 Milrila 46 Nivadil 47 Perdipine 48 Solinase 49 Vaprisol 50 R&D Projects 52 ASP ASP Vernakalant 52 YM YM Growth Forecast 56 UROLOGY 57 Marketed Products 57 Harnal/Omnic/Flomax 57 Vesicare 61 R&D Projects 63 YM Growth Forecast 64 INFLAMMATION & IMMUNOLOGY 65 Marketed Products 65 Atock/Foradil 65 Celecox 66 Intal 68 Prograf 69 R&D Projects 75 AGI ASK ASP015K 75 Growth Forecast 76 GASTROINTESTINAL 77 Marketed Products 77 Colonel (HSR 237) 77 Ganaton 77 Gaster/Pepcid 78 Nasea 81 R&D Projects 83 YM Growth Forecast 84 INFECTIOUS DISEASE 85 Marketed Products 85
3 Aimmugen 85 AmBisome 85 Cefamezin 87 Cefspan 88 Cefzon/Omnicef 89 Funguard/Mycamine 91 Geninax 94 Infergen/Advaferon 95 Targocid 96 R&D Projects 97 ASP Telavancin 97 Growth Forecast 100 CENTRAL NERVOUS SYSTEM 101 Marketed Products 101 Dogmatyl 101 Luvox 102 Myslee 104 Seroquel 105 R&D Projects 109 ACR ASP ASP ASP ASP Growth Forecast 112 DERMATOLOGY 113 Marketed Products 113 Amevive 113 Protopic 114 R&D Projects 119 Growth Forecast 120 METABOLIC 121 Marketed Products 121 Starsis 121 R&D Projects 123 ASP YM Growth Forecast 124 BONE DISORDERS 125 Marketed Products 125 InductOs 125 R&D Projects 127 Minodronate 127 Growth Forecast 129 ONCOLOGY 130 Marketed Products 130 Eligard 130 SMANCS 131 R&D Projects 133 AGS-16M AGS-8M4 133 ASP Degarelix 133 YM Growth Forecast 135 APPENDIX 1 - FINANCIAL PERFORMANCE 139
4 Full Year Results APPENDIX 2 - KEY CORPORATE EVENTS 142 APPENDIX 3 - KEY AGREEMENTS 143 Ajinomoto Co Inc 143 American BioScience Inc (ABS) 143 AtheroGenics Inc 143 Biogen Idec 144 Boehringer Ingelheim (BI) 144 Cardiome Pharma Corp 144 Carlsson Research AB 146 Cephalon Inc 146 CoMentis Inc 146 CV Therapeutics Inc (CVT) 146 Ferring Pharmaceuticals 147 FibroGen Inc 147 Gilead Sciences Inc 148 GlaxoSmithKline 148 Gloucester Pharmaceuticals Inc 149 Icagen Inc 150 Ilypsa Inc 150 Immuno-Biological Laboratories 151 Kirin Brewery 151 Metabolex Inc 151 MorphoSys AG 153 Mundipharma International 153 Nippon Kayaku Co Ltd 154 Novartis 154 Ono Pharmaceutical Co Ltd 154 Pfizer 154 Pharmagenesis Inc 155 Regeneron Pharmaceuticals Inc 155 sanofi-aventis 155 Senju Pharmaceutical Co Ltd 157 SymBio Pharmaceuticals Ltd 157 Taiho Pharmaceuticals Co Ltd 158 Taisho Toyama Pharmaceutical Co Ltd 158 TAP Pharmaceutical Products Inc 158 Tercica Inc 159 Theravance Inc 159 Wyeth 160 XenoPort Inc 160 Zeria Pharmaceutical Co Ltd 161 APPENDIX 4 - INFRASTR UCTURE 162 Research and Development Facilities 163 Manufacturing Facilities 164 APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES /JOINT VENTURES 166 Subsidiaries 166 Joint Ventures 169 APPENDIX 6 - PRODUCT INDEX 170 Index of Tables Principal Operating Results 1 Sales By Business Area 7 Sales By Destination 10 Sales By Origin 11 Operating Income (Loss) By Geographic Area 12 Total Assets By Geographical Area 13 Employees By Geographic Area 19 Recent Product Approvals 21 Major Products, Therapeutic Areas and Sales 29 Major Cardiovascular Products, Major Urology Products,
5 Major Inflammation & Immunology Products, Major Gastrointestinal Products, Major Infectious Disease Products, Major Central Nervous System Products, Major Dermatology Products, Major Metabolic Products, Major Oncology Products, Index of Charts Sales By Business Area 7 Sales By Destination 10 Sales By Origin 11 Operating Income (Loss) By Geographic Area 12 Total Assets By Geographical Area 13 Employees By Geographic Area, Sales of Current Top Ten Products (2003A-2013E) 20 Adenoscan Sales (2003A-2013E) 34 Cibenol Sales (2005A-2013E) 35 Dorner Sales (2003A-2013E) 37 Frandol Sales (2003A-2013E) 38 Regadenoson Sales (2009E-2015E) 40 Lipitor Sales (2003A-2013E) 42 Micardis Sales (2003A-2013E) 44 Nivadil Sales (2002A-2012E) 48 Perdipine Sales (2003A-2013E) 49 Vernakalant Sales (2009E-2015E) 54 Flomax/Harnal/Omnic Sales (2003A-2013E) 61 Vesicare Sales (2005A-2013E) 62 Celecox Sales (2008A-2015E) 67 Intal Sales (2003A-2013E) 69 Prograf Sales (2003A-2013E) 73 Gaster/Pepcid Sales (2003A-2013E) 80 Nasea Sales (2003A-2013E) 82 AmBisome Sales (2003A-2013E) 87 Cefamezin Sales (2003A-2013E) 88 Cefspan Sales (2003A-2013E) 89 Cefzon Sales (2003A-2013E) 91 Funguard Sales (2003A-2013E) 93 Geninax Sales (2008E-2015E) 95 Telavancin Sales (2009E-2014E) 98 Dogmatyl Sales (2003A-2013E) 102 Luvox Sales (2003A-2013E) 103 Myslee Sales (2003A-2013E) 105 Seroquel Sales (2003A-2013E) 108 Protopic Sales (2003A-2013E) 117 Starsis Sales (2003A-2013E) 122 Minodronate Sales (2009E-2015E) 128 Eligard Sales (2006A-2013E) 131 Sales, Costs and Operating Income 140 Profitability and Research Ratios 140 R&D Expenditure and Capital Expenditure 140 Current Assets, Liabilities and Ratio 141 Assets, Cash and Liquidity 141 Employees and Productivity 141 Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and sent to
6 Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.
7 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Web Address: Office Code: Astellas Pharma: Performance, Products, Pipeline and Potential OC8HJLORSOPTX Product Formats Please select the product formats and quantity you require: Quantity Hard Copy: EURO Euro Shipping/Handling * Electronic: EURO * Shipping/Handling is only charged once per order. Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)
8 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: American Express Diners Club Master Card Visa Cardholder's Name Cardholder's Signature Expiry Date Card Number CVV Number Issue Date (for Diners Club only) Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World
Brochure More information from
Brochure More information from http://www.researchandmarkets.com/reports/2375238/ Breast Imaging Technologies Market (Digital Mammography,3D Breast Tomosynthesis, Breast MRI, Breast Ultrasound, Molecular
More informationFujisawa Announce Financial Results for 1 st Quarter of FY 03/2005
July 30, 2004 Fujisawa Announce Financial Results for 1 st Quarter of FY 03/2005 Japan, July 30, 2004 Fujisawa Pharmaceutical Co., Ltd. today announced its financial results for the first quarter of fiscal
More informationMaximizing the Product Value
Business Review Review of Operations by Therapeutic Area Astellas is working to steadily grow and maximize the value of products developed through its investments over the years, including its growth drivers
More informationOncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
More informationH. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review
H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationThe National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile
The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationRussia Cardiac Assist Devices Market Outlook to 2021
Russia Cardiac Assist Devices Market Outlook to 2021 Russia Cardiac Assist Devices Market Outlook to 2021 BioPortfolio has been marketing business and market research reports from selected publishers for
More informationU.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon),
U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin,
More informationCOPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global
COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015-2022 COPD and
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationCochlear Implants - Medical Devices Pipeline Assessment, 2016
Cochlear Implants - Medical Devices Pipeline Assessment, 2016 Cochlear Implants - Medical Devices Pipeline Assessment, 2016 BioPortfolio has been marketing business and market research reports from selected
More informationNoninvasive Glucose Monitors Devices, Technologies, Players and Prospects
Report Prospectus Noninvasive Glucose Monitors Devices, Technologies, Players and Prospects 1 Improving Diabetes Management For diabetes patients, glucose monitoring is a way of life, a several-times-per-day
More informationPartnering for Growth
Partnering for Growth JP Morgan Healthcare Conference Simon Lowth, Chief Financial Officer, AstraZeneca 9 January 2013 Partnering for Growth Agenda Our platforms for growth Partnering strategy and capabilities
More informationTandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile
Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business
More informationAntifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles
Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin,
More informationChina Insulin Industry Report, Jan. 2011
China Insulin Industry Report, 2010 Jan. 2011 This report analyzes the status, competition pattern and development direction of the insulin industry Focuses on the operation and development prospect of
More informationSickle-cell Anemia Therapeutics Market in the US
Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sector Publishing Intelligence Limited (SPi) has been marketing business and market
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More information(City, State, Zip Code)
This Partner Agency Agreement, dated this day of, 2015, is between COMMUNITY FOOD SHARE, INC. (CFS), whose address is 650 South Taylor Avenue, Louisville, CO 80027, and (Partner Agency) whose address is
More informationOrally Inhaled Corticosteroids to 2022
Greystone Research Associates 1+603-595-4340 April 2015 Orally Inhaled Corticosteroids to 2022 Drugs, Devices, Markets and Forecasts Contents A Comprehensive Market Analysis Report Scope & Overview 2 Table
More informationNoninvasive Glucose Monitors to 2022
Noninvasive Glucose Monitors to 2022 Devices, Technologies, Players and Prospects Report Prospectus Greystone Research associates N o n i n v a s i v e G l u c o s e M o n i t o r s t o 2 0 2 2 Greystone
More informationDental Implants - Global Strategic Business Report
Brochure More information from http://www.researchandmarkets.com/reports/2228021/ Dental Implants - Global Strategic Business Report Description: This report analyzes the worldwide markets for Dental Implants
More informationDainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement
For immediate release April 28, 2005 Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement Dainippon Pharmaceutical Co., Ltd. Sumitomo Pharmaceuticals Co., Ltd. Dainippon Pharmaceutical
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationChina Human Vaccine Industry Report, May 2012
China Human Vaccine Industry Report, 2011-2012 May 2012 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight and
More informationInfertility Treatment Devices Market by Product (Cryosystem, Imaging System, Incubator, Micromanipulator, Ovum Aspiration Pump, Sperm Analyzer,
Infertility Treatment Devices Market by Product (Cryosystem, Imaging System, Incubator, Micromanipulator, Ovum Aspiration Pump, Sperm Analyzer, Workstation), Technology (AI, Gamete Donation, IVF, ICSI,
More informationSukhjit Starch And Chemicals Ltd - Company Capsule
Sukhjit Starch And Chemicals Ltd - Company Capsule Sukhjit Starch And Chemicals Ltd - Company Capsule The Business Research Store is run by Sector Publishing Intelligence Ltd. SPi has been selling professional
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationInsert Cover Image using Slide Master View Do not distort. Anti-Diabetic Pharmaceuticals Market - India
Insert Cover Image using Slide Master View Do not distort Anti-Diabetic Pharmaceuticals Market - India March 2012 Eecutive Summar Market Drivers and Challenges Drug Regulation and Patents Global Market
More informationNon Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018
Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase
More informationNorth America Cardiac Rhythm Management (CRM) Procedures Outlook to 2021
North America Cardiac Rhythm Management (CRM) Procedures Outlook to 2021 North America Cardiac Rhythm Management (CRM) Procedures Outlook to 2021 BioPortfolio has been marketing business and market research
More informationBaby-Sitting - $20 Per Day/Per Nanny (local clients) Less than 24 hours notice $30 Per Day/Per Nanny. Hotel Overnight Sitting - $35 per Day/Per Nanny
ALL ABOUT NANNIES BUSINESS PHONE: 602-266-9116 BUSINESS FACSIMILE: 602-266-9787 BUSINESS EMAIL: ADMIN@ALLABOUTNANNIESINC.COM TEMPORARY, BABY-SITTING, HOTEL & ON-CALL AS NEEDED Mother s Full Name: Place
More informationR&D Pipeline (May 2006)
R&D Pipeline (May 2006) 1Japan (1)Approved Product Name (Code No) Vesicare (YM905) Funguard (FK463) (Approval Date ) solifenacin (April 2006) micafungin (April 2006) Urinary frequency, urinary incontinence
More informationChina Animal Vaccine Industry Report, Jun 2012
China Animal Vaccine Industry Report, 2011-2012 Jun 2012 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight
More informationChina Oral Hypoglyceimic Agents (OHAs) Industry Report, Feb. 2011
China Oral Hypoglyceimic Agents (OHAs) Industry Report, 2010 Feb. 2011 This report Analyzes the status quo and prospect of Chinese OHAS Market. Related Products China Interventional Cardiovascular Device
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationAlpha-fetoprotein (AFP) Testing Market: By Cancer Type (Liver Cancer, Testes Cancer, Ovarian Cancer, Biliary Tract Cancer, Stomach Cancer, Pancreatic
Alpha-fetoprotein (AFP) Testing Market: By Cancer Type (Liver Cancer, Testes Cancer, Ovarian Cancer, Biliary Tract Cancer, Stomach Cancer, Pancreatic Cancer, Others (Cirrhosis, and Hepatitis)) & Geography-Forecast
More informationR&D Pipeline (November 2006)
R&D Pipeline (November 2006) 1Japan (1)Filed Code No Generic Name (Filing Date ) Therapeutic Target Classification YM177 celecoxib (Dec 2002) Rheumatoid arthritis, osteoarthritis, low back pain, etc Cyclooxygenase-II
More informationCriteria and Application for Men
Criteria and Application for Men Return completed form via fax or email to LIVESTRONG Foundation attn LIVESTRONG Fertility Fax 512.309.5515 email Cancer.Navigation@LIVESTRONG.org Made possible by participating
More informationOperational Efficiency:
Operational Efficiency: metrics that matter Copyright Altus Ltd 214. All rights reserved. Kevin Okell Consultancy Director 15/5/214 From distribution chain to value chain Ad-valorem pricing driven from
More informationR&D Pipeline (May 2010)
R&D Pipeline (May 2010) 1 Global development (1) Filed Stage in the Most Advanced Territory YM617 tamsulosin Alpha-1 receptor antagonist Lower urinary tract syndrome in male patients (June 2007) New indication
More informationSilica Fume Market by Application (Building Construction, Marine Structure Construction, Oil & Gas Well Grouting, Nuclear Power Plant Construction,
Silica Fume Market by Application (Building Construction, Marine Structure Construction, Oil & Gas Well Grouting, Nuclear Power Plant Construction, Chemical Production Facilities Construction, by Geography
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationDiabetic Retinopathy Treatment - Global Market Outlook ( )
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Diabetic Retinopathy Treatment - Global Market Outlook (2015-2022) Diabetic Retinopathy Treatment - Global Market
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationAtopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024
Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024 Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024 BioPortfolio has been marketing business and market research reports
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationDatamonitor Healthcare Pharma intelligence. GlaxoSmithKline: Company Analysis
Datamonitor Healthcare Pharma intelligence GlaxoSmithKline: Company Analysis OVERVIEW Latest Earnings Review Q2 2018 [27 July 2018] Click to view analysis Latest Forecast Update Q2 2018 [2 August 2018]
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationPharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationBariatric Surgery Devices - North America Analysis and Market Forecasts
Bariatric Surgery Devices - North America Analysis and Market Forecasts Bariatric Surgery Devices - North America Analysis and Market Forecasts BioPortfolio has been marketing business and market research
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationRegorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer
News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com Regorafenib from Bayer Submitted
More informationBRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationGlobal Vitamin Ingredients Market
Global Vitamin Ingredients Market 2016-2020 Global Vitamin Ingredients Market 2016-2020 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years.
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationChemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016
Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016 Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016 BioPortfolio has been marketing business
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationChina Silymarin Industry Overview,
China Silymarin Industry Overview, 2017-2021 China Silymarin Industry Overview, 2017-2021 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationEUROPE INFERTILITY (TESTING AND TREATMENT) MARKET FORECAST
EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET FORECAST 2017-2025 EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET FORECAST 2017-2025 BioPortfolio has been marketing business and market research reports
More informationChina Interventional Cardiovascular Device Industry Report, Jan. 2011
China Interventional Cardiovascular Device Industry Report, 2010 Jan. 2011 This report analyzes the social, economic and policy environments, the overall operation, market competition and development trends
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationPhone: +44 (0) or BioPortfolio Limited
Europe Neuromodulation Devices Market by Procedure [Internal Stimulation (DBS, GES, SNS, SCS, VNS), and External Stimulation (TENS, TMS)], and by Geography Analysis & Forecast to 2019 Europe Neuromodulation
More informationExhibitor Prospectus. Kalahari Resort & Convention Center 1305 Kalahari Drive Wisconsin Dells, WI 53965
Exhibitor Prospectus Kalahari Resort & Convention Center 1305 Kalahari Drive Wisconsin Dells, WI 53965 1 Conference Demographics The 29th Annual Autism Society of Wisconsin Conference will be held on April
More information2018 Business Associate Sponsorship Options
2018 Business Associate Sponsorship Options P.O. Box 790 - Sherwood, OR 97140 Phone (678) 523-5915 - Fax (877) 872-3493 - Email: main@ohiomgma.com - www.ohiomgma.com members are healthcare leaders and
More informationAstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.
[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS
More informationFood Service Industry Membership
Coeliac Western Australia Food Service Industry Membership Page 1 About Who we are Coeliac Western Australia (CWA) is a not-for-profit organisation established in 1979 to assist and support people who
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationHuman Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016
Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016 Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016 Sector Publishing Intelligence Limited (SPi) has been marketing business
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationRetiree Dental Open Enrollment
Retiree Dental Open Enrollment November 1 December 15, 2017 Open Enrollment Fact Sheet Delta Dental Information Sheet Delta Dental Enrollment Form Delta Dental Direct Debit Application Retiree Dental Plan
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationApproval for Manufacturing and Marketing of Micatrio
Press Release September 28, 2016 Nippon Boehringer Ingelheim Co., Ltd. Astellas Pharma Inc. Approval for Manufacturing and Marketing of Micatrio Combination Tablets, an Antihypertensive Drug Japan s first
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationFinancial Results for the 2Q/FY 2009 Ending March 31, November 6, 2009 Masafumi Nogimori President and CEO Astellas Pharma Inc.
Financial Results for the 2Q/FY 2009 Ending March 31, 2010 November 6, 2009 Masafumi Nogimori President and CEO Astellas Pharma Inc. Cautionary Statement Regarding Forward-Looking Information This material
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationChina Human Vaccine Industry Report, Jun. 2016
China Human Vaccine Industry Report, 2016-2020 Jun. 2016 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight
More informationMAKING STRIDES AGAINST BREAST CANCER OF THE UPPER VALLEY October 2, AM Storrs Pond Recreation Area, Hanover
MAKING STRIDES AGAINST BREAST CANCER OF THE UPPER VALLEY October 2, 2016 10 AM Storrs Pond Recreation Area, Hanover FOR MORE INFORMATION CONTACT: The Upper Valley Volunteer Planning Committee STAFF NAME:
More informationDravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015 BioPortfolio
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationInsulin Pens - Medical Devices Pipeline Assessment, 2016
Insulin Pens - Medical Devices Pipeline Assessment, 2016 Insulin Pens - Medical Devices Pipeline Assessment, 2016 Sector Publishing Intelligence Limited (SPi) has been marketing business and market research
More informationPoultry Diagnostics Market by Test (ELISA, PCR) Disease (Avian Salmonellosis, Avian Influenza, Newcastle Disease, Avian Pasteurellosis,
Poultry Diagnostics Market by Test (ELISA, PCR) Disease (Avian Salmonellosis, Avian Influenza, Newcastle Disease, Avian Pasteurellosis, Encephalomyelitis, Infectious Bronchitis), Service (Virology, Bacteriology,
More information2010 Sharing Hope Program for men
2010 Sharing Hope Program for men Criteria and Application Made possible by participating sperm banks and fertility centers Program Overview Goal Cancer patients have little opportunity to save for the
More informationExhibitor/Vendor Prospectus
Sickle Cell Disease Association of America, Inc. 5th Annual National Sickle Cell Walk with the Stars & Move-a-thon Canton Waterfront Park, Baltimore, MD August 18, 2018 Exhibitor/Vendor Prospectus SCDAA
More informationDental Floss (Oral Hygiene) Market in South Korea - Outlook to 2020: Market Size, Growth and Forecast Analytics
Dental Floss (Oral Hygiene) Market in South Korea - Outlook to 2020: Market Size, Growth and Forecast Analytics Dental Floss (Oral Hygiene) Market in South Korea - Outlook to 2020: Market Size, Growth
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More information